Close Menu

mergers & acquisitions

The acquisition of the CLIA-certified lab will accelerate development of Iris' NADiA platform.

The deal combines Axela's multiplex protein biomarker testing capabilities and Xceed's Ziplex System for gene expression analysis, with a focus on multiplex diagnostic assays.

Meridian Bioscience's acquisition of Bioline both provides Meridian a foothold in the PCR market and is expected to help drive future diagnostic development at the company.

The deal is expected to bolster Thermo's capabilities in PCR and quantitative real-time PCR.

MDRNA, now known as Marina Biotech, plans a 1-for-4 reverse stock split, which will enable it to have enough authorized shares to consummate the acquisition of Cequent.

Meridian has acquired the reagents maker, adding complementary products to its life science business. The firm also reported an 11 percent decline in Q3 revenues.

The acquisition will add reagents for nucleic acid and protein purification, restriction and modifying enzymes, and other life science research and diagnostic tools to Thermo's Analytical Technologies portfolio.

Merck KGaA has formed a new division, called EMD Millipore, which had pro forma revenues of around $2.9 billion in 2009.

The deal adds to Evotec research funds and potential milestone payments associated with DeveloGen's discovery alliance with Boehringer Ingelheim on small molecules to treat type 2 diabetes.

Through the first half of 2010, 33 deals were either completed or announced, and some industry experts said that more deals are anticipated ahead.


The New York Times reports on an effort to address in high school biology classes misconceptions regarding race and genetics.

60 Minutes speaks with Harvard's George Church about tackling the effects of aging and more.

In PLOS this week: rare alterations in Timothy syndrome, analysis of twins' gut microbiomes, and more.

A Brazilian-led team of researchers reports it has generated a sugarcane genome assembly that encompasses more than 99 percent of its genome.